Dyne Therapeutics Inc. has announced its financial results for the first quarter of 2025. The company reported a net loss of $115.4 million for the quarter ended March 31, 2025, compared to a net loss of $65.6 million for the same period in 2024. The R&D expenses for the quarter were $106.4 million, a significant increase from $44.5 million in the first quarter of 2024. General and administrative expenses decreased to $15.9 million from $24.6 million in the previous year. Dyne Therapeutics also highlighted recent business updates, including a Type C meeting with the FDA for DYNE-101 in DM1 held in May 2025. The company plans to provide a regulatory update following the receipt of meeting minutes. Furthermore, a Registrational Expansion Cohort of the ACHIEVE Trial of DYNE-101 in DM1 was initiated to support a potential submission for U.S. Accelerated Approval in the first half of 2026. Similarly, the Registrational Expansion Cohort of the DELIVER Trial of DYNE-251 in DMD is fully enrolled to support a potential submission for U.S. Accelerated Approval in early 2026. Dyne's cash, cash equivalents, and marketable securities totaled $677.5 million as of March 31, 2025. The company expects that this will be sufficient to fund its operations at least into the second half of 2026.